Guillain-Barré syndrome as the first manifestation of POEMS syndrome

Sójka, Monika; Gajos, Agata; Pigońska, Justyna; Bogucki, Marek; Tyfa, Krzysztof; Bogucki, Andrzej

doi:10.5114/ninp.2012.29136

Cited by 3 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies show that POEMS syndrome is often misdiagnosed as Waldenström's macroglobulinemia (WM), Guillain Barre syndrome, or chronic demyelinating neuropathy [12][13][14] (Table 1). Detection of IgG-λ type M protein or IgA-λ type M protein is necessary for a diagnosis of POEMS syndrome.…”

Section: Discussionmentioning

confidence: 99%

Daratumumab-RD InductionSequential Autologous Stem Cell Transplantation for a new diagnosed case of POEMS Syndrome with 17p deletion solitary plasmacytoma of bone

Wang,

Shi,

Cong

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Daratumumab-based induction therapy and autologous stem cell transplantation (ASCT) are the recommended treatments for plasma cell tumors such as multiple myeloma and amyloidosis; however, few reports have examined the utility of this treatment strategy for POEMS syndrome with solitary plasmacytoma of the bone.Case presentation A patient presented with POEMS syndrome. Although myasthenia was the primary manifestation, POEMS was accompanied by a solitary plasmacytoma of the bone harboring a 17p13.1 deletion. The overall neuropathy limitations scale (ONLS) score was 5 for both upper limbs and 7 for both lower limbs. After four cycles of induction therapy with daratumumab (Dara) plus lenalidomide and dexamethasone (Rd) immunofixation electrophoresis became negative, and complete remission of hematological and vascular endothelial growth factor (HRCR & VCR) was achieved. Subsequently, he received local radiotherapy (DT 5000cGy/25f), high-dose chemotherapy combined with ASCT, two cycles of Dara-Rd consolidation, and lenalidomide (10 mg/day) as maintenance. He has remained in continuous HRCR and VCR for 18 months, with an ONLS score of 3 for both upper limbs and 2 on both lower limbs, thereby restoring independent walking.Conclusions Dara-Rd induction followed by radiotherapy and ASCT appears to be a safe, effective, and promising strategy for POEMS syndrome with an isolated plasma cell tumor of the bone.

show abstract

Section: Discussionmentioning

confidence: 99%

Daratumumab-RD InductionSequential Autologous Stem Cell Transplantation for a new diagnosed case of POEMS Syndrome with 17p deletion solitary plasmacytoma of bone

Wang,

Shi,

Cong

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Polyneuropathy in POEMS Syndrome

Шишкина

Мухачева

Байдина

2020

РНЖ

View full text Add to dashboard Cite

A rare version of paraproteinemic hemablastosis, with the onset characterized by Peripheral Nerve Disease, is POEMS- syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein, Skin Changes). In the foreground of the clinical picture of this oncohematological disease is progressive sensorimotor polyneuropathy, which is the reason for the primary reference to a neurologist long before the provision of specialized hematological care. The article provides an overview of recent scientific publications devoted to this disease. Its pathogenetic mechanisms are discussed, as well as the basis of endothelial growth factor. The authors present their own clinical observation of a 62-year-old patient. The onset of the disease was characterized by polyneuropathy accompanied by changes in the M-protein index, organomegaly in the absence of bone-destructive changes, which made the diagnosis difficult. Additional clinical signs included fever, edema (ascites, exudative pleurisy), and hypoproteinemia, changes in peripheral blood (moderate leukocytosis with a decrease in the level of erythrocytes and platelets, which is atypical), kidney and cardiovascular damage. Despite the specific therapy, the patient’s condition was complicated by the development of infectious complications and was fatal. This clinical observation illustrates the need for a careful differential search for a possible cause of non-polyneuropathy of unknown genesis.

show abstract

Prevalence and risk factors for depression in newly diagnosed patients with POEMS syndrome

Zhang

Zhou

Zhang

et al. 2014

Leukemia & Lymphoma

View full text Add to dashboard Cite

This prospective study delineated the prevalence and risk factors for clinical depression in patients with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes). Using a PHQ-9 (Patient Health Questionnaire scale-9, which evaluates the severity of depressive symptoms) score cut-off ≥ 10, the prevalence of pretreatment depression was 38.0%. Based on multivariate logistic regression, higher ONLS (Overall Neuropathy Limitation Scale, which assesses the severity of neuropathy) upper limb scores (hazard ratio [HR] 1.75; 95% confidence interval [CI] 1.09-2.81; p = 0.02) and ascites (HR 4.30; 95% CI 1.03-17.9; p = 0.04) were significant and independent predictors for depression. The incidence of post-treatment depression was 1.53% by the end of follow-up, while no patients received antidepressants. A preliminary logistic regression suggested depression to be a risk factor for early death (within 3 months after diagnosis) (HR 9.77; 95% CI, 1.08-88.9; p = 0.04).

show abstract

Guillain-Barré syndrome as the first manifestation of POEMS syndrome

Cited by 3 publications

References 14 publications

Daratumumab-RD InductionSequential Autologous Stem Cell Transplantation for a new diagnosed case of POEMS Syndrome with 17p deletion solitary plasmacytoma of bone

Daratumumab-RD InductionSequential Autologous Stem Cell Transplantation for a new diagnosed case of POEMS Syndrome with 17p deletion solitary plasmacytoma of bone

Polyneuropathy in POEMS Syndrome

Prevalence and risk factors for depression in newly diagnosed patients with POEMS syndrome

Contact Info

Product

Resources

About